NASDAQ:SNDX
Syndax Pharmaceuticals Inc Stock News
$20.92
-1.02 (-4.65%)
At Close: May 16, 2024
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Call Transcript
11:52am, Sunday, 06'th Nov 2022
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive
Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
07:00am, Thursday, 27'th Oct 2022
WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today anno
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call Transcript
07:55pm, Monday, 08'th Aug 2022
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive O
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
04:34pm, Monday, 08'th Aug 2022
Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
12:50pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
10:32am, Thursday, 04'th Aug 2022
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "
Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?
01:55pm, Monday, 01'st Aug 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?
11:37am, Monday, 01'st Aug 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Syndax Announces Participation at Two Upcoming Investor Conferences
07:00am, Thursday, 26'th May 2022
WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipelin
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
10:25pm, Monday, 09'th May 2022 Zacks Investment Research
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022
02:07pm, Monday, 11'th Apr 2022 Benzinga
Upgrades
Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $0.41 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the st
Do Penny Stocks Ever Make Money? Here Are 7 Success Stories
07:30am, Sunday, 10'th Apr 2022
Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021.
Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
04:59am, Friday, 08'th Apr 2022 Seeking Alpha
Syndax’s lead product candidates include SNDX-5613 and SNDX-6352. Click here to read about its growth prospects and my recommendation.
Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
12:59am, Friday, 08'th Apr 2022
Today's $19 share quote is backed by as much as $7.50 in cash vs. total liabilities under $1 per unit. Larger drug trials are underway testing the usefulness of two cancer-related products.
Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Is An Exciting Stock To Watch.
05:00pm, Saturday, 12'th Mar 2022 Stocks Register
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.60% to the previous day’s close as strong demand from buyers drove the stock to $16.85. Actively observing the price movement in the last trading, the stock closed the session at $17.48, falling within a range of $16.84 … Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Is An Exciting Stock To Watch. Read More »